We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · August 10, 2020

Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for Patients With Recent HCV Infection

Hepatology (Baltimore, Md.)

 

Additional Info

Hepatology (Baltimore, Md.)
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection
Hepatology 2020 Jul 01;72(1)7-18, M Martinello, C Orkin, G Cooke, S Bhagani, E Gane, R Kulasegaram, D Shaw, E Tu, K Petoumenos, P Marks, J Grebely, GJ Dore, M Nelson, GV Matthews

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading